MOTS-c
mitochondrial open reading frame of the 12S rRNA type-c · C101H152N28O22S2 · monoisotopic 2173.0918 Da. The index holds 112 assay reports on this compound across 21 batches from 12 suppliers.
Analytical fingerprint
Hand-authored chemistry. These properties describe the substance and do not change when a record is added.
MOTS-c has two methionines and consequently a characteristic oxidation ladder: main peak, mono-sulfoxide at −0.38 min, bis-sulfoxide at −0.66 min. The ladder is diagnostic — if a report shows a single early impurity but no second rung, the sample was probably not oxidised and the peak is something else. The index's MOTS-c records show the highest sulfoxide levels of any short peptide it tracks, which is consistent with its being shipped without cold packs more often than not.
- Compound class
- Metabolic and mitochondrial peptides
- Molecular formula
- C101H152N28O22S2
- Monoisotopic mass
- 2173.0918Da
- Average mass
- 2174.61Da
- Residues
- 16
- Nominal retention (RG-2, 30 min)
- 10.42min
- Retention window
- 0.30min
- Counter-ion as usually shipped
- acetate
- Typical label claims
- 5 mg · 10 mg
- Analytical difficulty (index scale)
- 1.00 — straightforward
- Purity is a defined quantity
- YES
Representative chromatogram
Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.
What the index has observed
Arithmetic over the 112 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.
By supplier
Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.
Characteristic impurities and degradants
The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.
| Named species | ΔRT (min, RG-2) | Δ mass (Da) | Seen in | Median % area | Max % area |
|---|---|---|---|---|---|
| des-Met1 (−131 Da) | +0.22 | -131.040 | 96% | 0.14 | 1.49 |
| Met1 sulfoxide (+16 Da) | -0.38 | +15.995 | 94% | 0.19 | 1.86 |
| bis-sulfoxide (+32 Da) | -0.66 | +31.990 | 90% | 0.24 | 1.83 |
| deamidated (+1 Da) | -0.30 | +0.984 | 89% | 0.15 | 1.51 |
Degradation pathways
- double methionine oxidation — MOTS-c carries two Met residues and both oxidise
- N-terminal Met excision during expression-derived production
Full impurity profile, with what each named species implies about the synthesis →
Quarterly coverage
Most recent records
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041952 | TFC | TFC-2605-R4770 | PeptideMeter | 2026-Q2 | 99.65 | 5.60 | 95.5 | Supplier-supplied | 0 | PASS |
| AX-2026-043416 | WXT | WXT-2511-P4848 | Janoshik | 2026-Q2 | 98.23 | 5.14 | 106.7 | Supplier-supplied | 0 | PASS |
| AX-2026-043149 | SSA | SSA-2511-W7415 | Janoshik | 2026-Q2 | 98.00 | 5.42 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043498 | BCH | BCH-2511-L5815 | Janoshik | 2026-Q2 | 96.96 | 3.75 | 93.4 | Supplier-supplied | 0 | FAIL |
| AX-2026-043150 | SSA | SSA-2511-W7415 | Janoshik | 2026-Q2 | 98.33 | 5.76 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043152 | SSA | SSA-2511-W7415 | Janoshik | 2026-Q2 | 98.64 | 5.48 | 88.9 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041953 | TFC | TFC-2605-R4770 | Janoshik | 2026-Q2 | 99.72 | 5.27 | 90.8 | Supplier-supplied | 2 | FAIL |
| AX-2026-043153 | SSA | SSA-2511-W7415 | Medutest | 2026-Q2 | 98.78 | 5.52 | — | Supplier-supplied | 0 | PASS |
| AX-2026-043499 | BCH | BCH-2511-L5815 | Medutest | 2026-Q2 | 97.04 | 3.58 | — | Buyer-sourced | 0 | FAIL |
| AX-2026-043151 | SSA | SSA-2511-W7415 | Janoshik | 2026-Q2 | 97.58 | 6.06 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-043154 | SSA | SSA-2511-W7415 | Janoshik | 2026-Q2 | 97.76 | 6.00 | 92.3 | Supplier-supplied | 0 | FAIL |
| AX-2026-043586 | QST | QST-2511-H7867 | PeptideMeter | 2026-Q2 | 98.06 | 5.19 | 97.7 | Supplier-supplied | 0 | PASS |
| AX-2026-043431 | WXT | WXT-2512-K4589 | Janoshik | 2026-Q1 | 98.81 | 2.12 | 91.7 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043581 | BCH | BCH-2601-S7929 | Janoshik | 2026-Q1 | 98.31 | 6.51 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043583 | BCH | BCH-2601-S7929 | PeptideMeter | 2026-Q1 | 97.84 | 6.60 | 105.3 | Supplier-supplied | 0 | FAIL |
| AX-2026-043430 | WXT | WXT-2512-K4589 | Janoshik | 2026-Q1 | 97.64 | 1.40 | 101.6 | Supplier-supplied | 1 | FAIL |
| AX-2026-043582 | BCH | BCH-2601-S7929 | PeptideMeter | 2026-Q1 | 97.59 | 6.19 | 102.0 | Supplier-supplied | 0 | FAIL |
| AX-2026-043432 | WXT | WXT-2512-K4589 | Janoshik | 2026-Q1 | 97.92 | 2.47 | 90.0 | Supplier-supplied | 1 | FAIL |
| AX-2026-043584 | BCH | BCH-2601-S7929 | Kestrel | 2026-Q1 | 98.50 | 6.49 | 88.7 | Supplier-supplied | 2 | FAIL |
| AX-2026-043559 | BCH | BCH-2601-U7218 | Janoshik | 2026-Q1 | 98.40 | 5.76 | 93.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042805 | GGPeps | GGPE-2508-J1903 | Janoshik | 2025-Q4 | 98.74 | 4.68 | 100.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042806 | GGPeps | GGPE-2508-J1903 | VendorInvestigate | 2025-Q4 | 98.71 | 3.74 | 96.1 | Buyer-sourced | 1 | MARGINAL |
| AX-2025-020239 | GGPeps | GGPE-2508-J1903 | Kestrel | 2025-Q4 | 99.37 | 5.08 | 102.0 | Supplier-supplied | 0 | PASS |
| AX-2025-020234 | GGPeps | GGPE-2508-J1903 | Janoshik | 2025-Q4 | 98.44 | 4.41 | 93.2 | Supplier-supplied | 0 | PASS |
| AX-2025-020238 | GGPeps | GGPE-2508-J1903 | Medutest | 2025-Q4 | 98.89 | 4.32 | — | Supplier-supplied | 0 | PASS |